Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03228433 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

A Phase 1 study, sponsored by Takeda.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT03228433 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03228433, a Phase 1 study, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and tolerability of TAK-418 following single oral doses in healthy participants.

Interventions

  • DRUG TAK-418
  • DRUG TAK-418 Placebo

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2017-07-21
Est. Completion 2018-05-12
Phase Phase 1

Sponsor

Takeda

408 total trials

What the Registry Record Tells You About NCT03228433

The ClinicalTrials.gov registry entry for NCT03228433 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which TAK-418 is the first listed.

NCT03228433 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03228433 about?

NCT03228433 is a clinical study titled "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants". The purpose of this study is to evaluate the safety and tolerability of TAK-418 following single oral doses in healthy participants.

What is the current status of trial NCT03228433?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-07-21. Estimated completion is 2018-05-12.

What interventions are being tested in trial NCT03228433?

The interventions under investigation include: TAK-418 (DRUG), TAK-418 Placebo (DRUG).

Who is sponsoring clinical trial NCT03228433?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.